![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Tzaridis, Theophilos; Schaefer, Niklas; Weller, Johannes; Steinbach, Joachim-Peter; Schlegel, Uwe; Seidel, Sabine; Sabel, Michael; Hau, Peter; Seidel, Clemens; Krex, Dietmar; Goldbrunner, Roland; Tonn, Jörg-Christian; Grauer, Oliver; Kebir, Sied; Schneider, Matthias; Schaub, Christina; Vatter, Hartmut; Coch, Christoph; Glas, Martin; Fimmers, Rolf; Pietsch, Torsten; Reifenberger, Guido; Herrlinger, Ulrich und Felsberg, Jörg
(2020):
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
In: International Journal of Cancer, Bd. 148, Nr. 7: S. 1695-1707
Kebir, Sied; Schaub, Christina; Junold, Nina; Hattingen, Elke; Schäfer, Niklas; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Goldbrunner, Roland; Galldiks, Norbert; Weller, Johannes; Mack, Frederic; Tzaridis, Theophilos; Baehr, Oliver; Seidel, Clemens; Schlegel, Uwe; Schmidt-Graf, Friederike; Rohde, Veit; Borchers, Christian; Tabatabai, Ghazaleh; Haenel, Mathias; Sabel, Michael; Gerlach, Rüdiger; Krex, Dietmar; Belka, Claus; Vatter, Hartmut; Proescholdt, Martin; Glas, Martin und Herrlinger, Ulrich
(2019):
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
In: Journal of Neuro-Oncology, Bd. 144, Nr. 3: S. 501-509
Herrlinger, Ulrich; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Sabel, Michael; Hau, Peter; Kortmann, Rolf-Dieter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Schnell, Oliver; Baehr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Kowalski, Thomas; Ringel, Florian; Schmidt-Graf, Friederike; Suchorska, Bogdana; Brehmer, Stefanie; Weyerbrock, Astrid; Renovanz, Miriam; Bullinger, Lars; Galldiks, Norbert; Vajkoczy, Peter; Misch, Martin; Vatter, Hartmut; Stuplich, Moritz; Schäfer, Niklas; Kebir, Sied; Weller, Johannes; Schaub, Christina; Stummer, Walter; Tonn, Jörg-Christian; Simon, Matthias; Keil, Vera C.; Nelles, Michael; Urbach, Horst; Coenen, Martin; Wick, Wolfgang; Weller, Michael; Fimmers, Rolf; Schmid, Matthias; Hattingen, Elke; Pietsch, Torsten; Coch, Christoph und Glas, Martin
(2019):
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
In: Lancet, Bd. 393, Nr. 10172: S. 678-688
Schäfer, Niklas; Pröscholdt, Martin; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Grauer, Oliver; Goldbrunner, Roland; Friedrich, Franziska; Rohde, veit; Ringel, Florian; Schlegel, Uwe; Sabel, Michael; Ronellenfitsch, Michael W.; Uhl, Martin; Grau, Stefan; Hänel, Mathias; Schnell, Oliver; Krex, Dietmar; Vajkoczy, Peter; Tabatabai, Ghazaleh; Mack, Frederic; Schaub, Christina; Tzaridis, Theophilos; Niessen, Michael; Kebir, Sied; Leutgeb, Barbara; Urbach, Horst; Belka, Claus; Stummer, Walter; Glas, Martin und Herrlinger, Ulrich
(2018):
Quality of life in the GLARIUS trial randomizing bevacizumab/ irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
In: Neuro-Oncology, Bd. 20, Nr. 7: S. 975-985
Schaub, Christina; Kebir, Sied; Junold, Nina; Hattingen, Elke; Schäfer, Niklas; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Goldbrunner, Roland; Niessen, Michael; Mack, Frederic; Stuplich, Moritz; Tzaridis, Theophilos; Bähr, Oliver; Kortmann, Rolf-Dieter; Schlegel, Uwe; Schmidt-Graf, Friederike; Rohde, Veit; Braun, Christian; Haenel, Mathias; Sabel, Michael; Gerlach, Rüdiger; Krex, Dietmar; Belka, Claus; Vatter, Hartmut; Pröscholdt, Martin; Herrlinger, Ulrich und Glas, Martin
(2018):
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
In: Journal of Cancer Research and Clinical Oncology, Bd. 144, Nr. 8: S. 1581-1589
Herrlinger, Ulrich; Schäfer, Niklas; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Goldbrunner, Roland; Friedrich, Franziska; Rohde, Veit; Ringel, Florian; Schlegel, Uwe; Sabel, Michael; Ronellenfitsch, Michael W.; Uhl, Martin; Maciaczyk, Jaroslaw; Grau, Stefan; Schnell, Oliver; Hänel, Mathias; Krex, Dietmar; Vajkoczy, Peter; Gerlach, Rüdiger; Kortmann, Rolf-Dieter; Mehdorn, Maximilian; Tüttenberg, Jochen; Mayer-Steinacker, Regine; Fietkau, Rainer; Brehmer, Stefanie; Mack, Frederic; Stuplich, Moritz; Kebir, Sied; Kohnen, Ralf; Dunkl, Elmar; Leutgeb, Barbara; Proescholdt, Martin; Pietsch, Torsten; Urbach, Horst; Belka, Claus; Stummer, Walter und Glas, Martin
(2016):
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O-6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
In: Journal of Clinical Oncology, Bd. 34, Nr. 14:
1611-U134
Korfel, Agnieszka; Schlegel, Uwe; Herrlinger, Ulrich; Dreyling, Martin; Schmidt, Christian; Baumgarten, Luisa von; Pezzutto, Antonio; Grobosch, Thomas; Kebir, Sied; Thiel, Eckhard; Martus, Peter und Kiewe, Philipp
(2016):
Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma.
In: Journal of Clinical Oncology, Bd. 34, Nr. 15: S. 1757-1763